Sinovac Biotech (SVA) 20-F2014 FY Annual report (foreign)

Filed: 29 Apr 15, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. freshman Avg

New words: adult, alleviate, Anfluand, Bangladesh, biggest, Biotec, breakthrough, breathing, budgeting, Chile, circulating, commonly, condensed, CSRC, decade, dispute, Dohme, dossier, Endgame, entrance, eradicate, Eradication, EU, expedited, extremely, fine, footnote, fourth, habitually, headcount, hereunder, immobilized, index, insignificant, intestine, INTRAVACC, invade, IPV, irreversible, Merck, methodology, omitted, OPV, Orbimed, paralytic, paralyzed, partly, PCV, penal, permanent, pharmacovigilance, polio, problem, rare, reinvestment, resource, restart, restarted, role, Roundtrip, routine, Sabin, safer, Salk, SAT, secondary, settle, Simplifying, sIPV, surveillance, swap, Tajikistan, text, thereto, TusHoldingsCo, Vaccinology, VAPP, vehicle

Removed: absolute, achieved, affiliate, Aleph, analytical, announcement, ascertained, assembly, attractive, base, branch, capture, carryforward, cell, clinician, CNK, cohort, comparison, consultation, cultured, Delta, discouraged, dynamic, EV, eventual, extension, formal, grandfathering, grow, inflation, injure, integrity, interim, Jingang, length, MOA, onshore, Pacific, partially, participation, pegging, pharmacopoeia, precisely, prevented, priced, producing, reaching, realigned, reexamine, remedied, requiring, restriction, retention, RimAsia, Salomon, Sino, standardized, static, subsidy, Topsec, vero, veterinary, VICH, wider, workshop

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

SVA similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 15.1

Consent of Independent Registered Public Accounting Firm

We consent to the incorporation by reference in the Registration Statement on Form S-8 (No. 333-161827) pertaining to Sinovac Biotech Ltd.’s 2003 Stock Option Plan and the Registration Statement on Form S-8 (No. 333-190980) pertaining to Sinovac Biotech Ltd.’s 2012 Share Incentive Plan of our reports dated April 29, 2015, with respect to the consolidated financial statements of Sinovac Biotech Ltd. and the effectiveness of internal control over financial reporting of Sinovac Biotech Ltd., included in this Annual Report on Form 20-F of Sinovac Biotech Ltd. for the year ended December 31, 2014.

/s/ Ernst & Young Hua Ming LLP

Beijing, The People’s Republic of China
April 29, 2015